“The present condition has uncovered some structural weaknesses while in the EU’s medicines source chain plus a high dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides claimed. She proposed that supply chain issues be addressed within an EU pharmaceutical technique anticipated to become launched by the tip with